JP2017526728A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017526728A5 JP2017526728A5 JP2017514446A JP2017514446A JP2017526728A5 JP 2017526728 A5 JP2017526728 A5 JP 2017526728A5 JP 2017514446 A JP2017514446 A JP 2017514446A JP 2017514446 A JP2017514446 A JP 2017514446A JP 2017526728 A5 JP2017526728 A5 JP 2017526728A5
- Authority
- JP
- Japan
- Prior art keywords
- montelukast
- medicament
- combination
- disease
- virus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 19
- UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 claims 13
- 229960005127 montelukast Drugs 0.000 claims 13
- ZKLPARSLTMPFCP-OAQYLSRUSA-N 2-[2-[4-[(R)-(4-chlorophenyl)-phenylmethyl]-1-piperazinyl]ethoxy]acetic acid Chemical compound C1CN(CCOCC(=O)O)CCN1[C@@H](C=1C=CC(Cl)=CC=1)C1=CC=CC=C1 ZKLPARSLTMPFCP-OAQYLSRUSA-N 0.000 claims 9
- 229960001508 levocetirizine Drugs 0.000 claims 9
- 208000036142 Viral infection Diseases 0.000 claims 4
- 230000009385 viral infection Effects 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 3
- 206010012289 Dementia Diseases 0.000 claims 3
- 241000725619 Dengue virus Species 0.000 claims 3
- 241001115402 Ebolavirus Species 0.000 claims 3
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 3
- 208000023105 Huntington disease Diseases 0.000 claims 3
- 208000009829 Lewy Body Disease Diseases 0.000 claims 3
- 201000002832 Lewy body dementia Diseases 0.000 claims 3
- 208000018737 Parkinson disease Diseases 0.000 claims 3
- 241000710886 West Nile virus Species 0.000 claims 3
- 241000710772 Yellow fever virus Species 0.000 claims 3
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims 3
- 230000001404 mediated effect Effects 0.000 claims 3
- 230000004770 neurodegeneration Effects 0.000 claims 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims 3
- 229940051021 yellow-fever virus Drugs 0.000 claims 3
- 208000004006 Tick-borne encephalitis Diseases 0.000 claims 2
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 claims 1
- 206010061218 Inflammation Diseases 0.000 claims 1
- 208000012902 Nervous system disease Diseases 0.000 claims 1
- 208000025966 Neurological disease Diseases 0.000 claims 1
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims 1
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 230000002757 inflammatory effect Effects 0.000 claims 1
- 230000004054 inflammatory process Effects 0.000 claims 1
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 238000013268 sustained release Methods 0.000 claims 1
- 239000012730 sustained-release form Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462050668P | 2014-09-15 | 2014-09-15 | |
| US62/050,668 | 2014-09-15 | ||
| PCT/US2015/049767 WO2016044095A1 (en) | 2014-09-15 | 2015-09-11 | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020070422A Division JP2020109128A (ja) | 2014-09-15 | 2020-04-09 | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017526728A JP2017526728A (ja) | 2017-09-14 |
| JP2017526728A5 true JP2017526728A5 (enExample) | 2018-10-11 |
Family
ID=55533713
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017514446A Pending JP2017526728A (ja) | 2014-09-15 | 2015-09-11 | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
| JP2020070422A Pending JP2020109128A (ja) | 2014-09-15 | 2020-04-09 | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020070422A Pending JP2020109128A (ja) | 2014-09-15 | 2020-04-09 | 炎症介在性状態の治療におけるレボセチリジン及びモンテルカスト |
Country Status (4)
| Country | Link |
|---|---|
| US (4) | US9925183B2 (enExample) |
| EP (1) | EP3193875B1 (enExample) |
| JP (2) | JP2017526728A (enExample) |
| WO (1) | WO2016044095A1 (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX352824B (es) | 2010-06-16 | 2017-12-11 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación. |
| AU2014249531B2 (en) | 2013-03-13 | 2018-11-29 | IRR, Inc. | Use of levocetirizine and montelukast in the treatment of traumatic injury |
| RU2015134423A (ru) | 2013-03-13 | 2017-04-26 | Инфламматори Респонс Ресёрч, Инк. | Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств |
| EP2968309A4 (en) | 2013-03-13 | 2016-08-31 | Inflammatory Response Res Inc | USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY |
| WO2016044095A1 (en) | 2014-09-15 | 2016-03-24 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
| CN120570898A (zh) * | 2018-04-27 | 2025-09-02 | 雷莫内克斯生物制药有限公司 | 用于预防或治疗黄病毒感染症的药物组合物 |
| WO2019209035A1 (ko) * | 2018-04-27 | 2019-10-31 | 주식회사 레모넥스 | 플라비바이러스 감염증의 예방 또는 치료용 약학적 조성물 |
| US10966943B2 (en) | 2018-09-06 | 2021-04-06 | Innopharmascreen Inc. | Methods and compositions for treatment of asthma or parkinson's disease |
| MX2021002657A (es) * | 2018-09-14 | 2021-07-21 | Jiangyin Usun Pharmaceutical Co Ltd | Nuevos conjugados de montelukast y péptidos. |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| EP4114433A2 (en) * | 2020-03-02 | 2023-01-11 | Pharma Mar S.A. | Compounds for use in viral infections |
| US20230158104A1 (en) * | 2020-03-02 | 2023-05-25 | Pharma Mar, S.A. | Compounds for use in autoimmune conditions |
| WO2021236518A1 (en) * | 2020-05-19 | 2021-11-25 | IRR, Inc. | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof |
| KR102935859B1 (ko) | 2022-08-12 | 2026-03-06 | 아주대학교산학협력단 | 펙소페나딘을 포함하는 퇴행성 신경질환의 예방, 개선 또는 치료용 조성물 |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4801612A (en) | 1986-07-03 | 1989-01-31 | Regents Of The University Of California | Method of inhibiting inflammatory response |
| US5211958A (en) | 1987-11-30 | 1993-05-18 | Gist-Brocades, N.V. | Pharmaceutical composition and process for its preparation |
| US5147637A (en) | 1988-06-07 | 1992-09-15 | The Rockefeller University | Method of inhibiting the influx of leukocytes into organs during sepsis or other trauma |
| DE69226372T2 (de) | 1991-11-14 | 1999-04-01 | Alliance Pharmaceutical Corp., San Diego, Calif. | Vorrichtung zur teilweisen flüssigen beatmung mit fluorkohlenwasserstoffen |
| WO1995009652A1 (en) | 1993-10-06 | 1995-04-13 | The Kennedy Institute For Rheumatology | Treatment of autoimmune and inflammatory disorders |
| JP2001511134A (ja) | 1997-01-24 | 2001-08-07 | オートイミューン インク | メトトレキサートと組合せる耐性化を用いる自己免疫疾患の治療 |
| NZ520907A (en) | 1997-12-23 | 2004-05-28 | Schering Corp | Composition for treating respiratory and skin diseases, comprising at least one leukotriene antagonist and at least one antihistamine |
| WO1999037155A1 (en) | 1998-01-27 | 1999-07-29 | Nutramax Laboratories, Inc. | Combinations of tyrosine, methylating agents, phospholipids, fatty acids, and st. john's wort for the treatment of mental disturbances |
| US6384038B1 (en) | 1998-04-14 | 2002-05-07 | Sepracor Inc. | Methods and compositions using cetirizine in combination with leukotriene inhibitors or decongestants |
| US7186555B1 (en) | 1999-04-13 | 2007-03-06 | The Feinstein Institute For Medical Research | Prevention of brain damage in stroke |
| US20020006961A1 (en) | 1999-05-14 | 2002-01-17 | Katz Stanley E. | Method and composition for treating mammalian nasal and sinus diseases caused by inflammatory response |
| DE10007203A1 (de) | 2000-02-17 | 2001-08-23 | Asta Medica Ag | Neue Kombination nichtsedierender Antihistaminika mit Substanzen, die die Leukotrienwirkung beeinflussen, zur Behandlung der Rhinitis/Konjunktivitis |
| US20010051624A1 (en) | 2000-04-12 | 2001-12-13 | Jones Thomas R. | Method and compositions for the treatment of allergic conditions using PGD2 receptor antagonists |
| US20020052312A1 (en) | 2000-05-30 | 2002-05-02 | Reiss Theodore F. | Combination therapy of chronic obstructive pulmonary disease using muscarinic receptor antagonists |
| EP1307189B1 (en) | 2000-07-28 | 2006-05-10 | Immupharm APS | Use of hydroxyethylrutosides for treating symptoms of common cold, allergic rhinitis and infections relating to the respiratory tract |
| US7718198B2 (en) | 2001-06-20 | 2010-05-18 | Metaproteomics, Llc | Treatment modalities for autoimmune diseases |
| SI1404304T1 (sl) | 2001-06-28 | 2009-10-31 | Ucb Farchim Sa Z I Planchy | Tableta, obsegajoča cetirizin in psevdoefedrin |
| EP1471907B1 (en) | 2001-06-29 | 2008-07-16 | AB Science | Use of c-kit inhibitors for treating autoimmune diseases |
| HU224941B1 (en) | 2001-08-10 | 2006-04-28 | Bgi Innovacios Kft | Phototerapy apparatus |
| WO2003101434A2 (en) | 2001-12-21 | 2003-12-11 | Sampad Bhattacharya | Intranasal pharmaceutical compositions comprising an antihistamine and a leukotriene inhibitor |
| DE50312523D1 (de) * | 2002-05-24 | 2010-04-29 | Carl-Fr Coester | Pharmazeutische wirkstoffkombination sowie deren verwendung |
| US7291331B1 (en) | 2002-09-11 | 2007-11-06 | La Jolla Institute For Allergy And Immunology | Methods of treating OX40 medicated recall immune responses |
| US20040180868A1 (en) | 2003-03-12 | 2004-09-16 | Mullally John P. | Composition and method for treating inflammations by reducing C-reactive protein |
| US7666417B2 (en) | 2003-04-22 | 2010-02-23 | Fred Hutchinson Cancer Research Center | Methods and compositions for treating autoimmune diseases or conditions |
| US20060263350A1 (en) | 2003-09-26 | 2006-11-23 | Fairfield Clinical Trials Llc | Combination antihistamine medication |
| WO2006010283A1 (en) | 2004-07-28 | 2006-02-02 | Universität Zürich | Prevention and treatment of thrombus formation |
| RU2411956C2 (ru) | 2004-10-05 | 2011-02-20 | Дженентек, Инк. | Способ лечения васкулита |
| US20070244128A1 (en) | 2005-11-04 | 2007-10-18 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| US20070225285A1 (en) * | 2005-11-04 | 2007-09-27 | Amira Pharmaceuticals, Inc. | 5-lipoxygenase-activating protein (flap) inhibitors |
| WO2007056510A2 (en) | 2005-11-09 | 2007-05-18 | The Children's Hospital Of Philadelphia | Chloride transport upregulation for the treatment of traumatic brain injury |
| WO2007071313A2 (en) | 2005-12-21 | 2007-06-28 | Meda Pharma Gmbh & Co Kg | Combination of anticholinergics, glucocorticoids, beta2-ag0nists, pde4 inhibitor and antileukotriene for the treatment of inflammatory diseases |
| US7589076B2 (en) | 2006-05-18 | 2009-09-15 | Pgx Health, Llc | Substituted aryl piperidinylalkynyladenosines as A2AR agonists |
| EP2170317A4 (en) | 2007-02-12 | 2011-03-23 | Mike Nicolaou | TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), GASTRO-OESOPHAGEAL REFLUX DISEASE (GERD), FOOD ALLERGIES, AND OTHER DISEASES AND GASTROINTESTIN DISORDERS AFFECTED BY APPROPRIATE MANAGEMENT OF HISTAMINE USING A COMBINATION OF INHIBITORS HISTIDINE DECARBOXYLASE, MEDICAMEN |
| EP2650303A1 (en) | 2007-02-26 | 2013-10-16 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of heart failure and other disorders |
| EP2175856A4 (en) | 2007-08-15 | 2011-08-24 | Chemagis Ltd | NOVEL PROCESS FOR THE PREPARATION OF HIGH-PURITY LEVOCETRIXIN AND ITS SALTS |
| US20090227018A1 (en) | 2007-10-25 | 2009-09-10 | Revalesio Corporation | Compositions and methods for modulating cellular membrane-mediated intracellular signal transduction |
| AU2008316284A1 (en) | 2007-10-25 | 2009-04-30 | Merck Frosst Canada Ltd. | Novel crystalline salts of montelukast |
| JP5613565B2 (ja) | 2007-10-25 | 2014-10-22 | リバルシオ コーポレイション | 細胞膜媒介細胞内シグナル伝達を調節するための組成物および方法 |
| US8946265B2 (en) | 2009-03-02 | 2015-02-03 | Generics [Uk] Limited | Process for the preparation of lenalidomide |
| WO2010107404A1 (en) | 2009-03-16 | 2010-09-23 | Mahmut Bilgic | Stable pharmaceutical combinations |
| US8263581B2 (en) | 2009-07-03 | 2012-09-11 | Jdp Therapeutics, Inc. | Non-sedating antihistamine injection formulations and methods of use thereof |
| GB2474748B (en) | 2009-10-01 | 2011-10-12 | Amira Pharmaceuticals Inc | Polycyclic compounds as lysophosphatidic acid receptor antagonists |
| US20130030000A1 (en) | 2010-01-28 | 2013-01-31 | Chobanian Harry R | Pharmaceutical compositions for the treatment of pain and other indications |
| MX352824B (es) | 2010-06-16 | 2017-12-11 | Inflammatory Response Res Inc | Uso de levocetirizina y montelukast en el tratamiento de influenza, resfriado común e inflamación. |
| US20120002637A1 (en) | 2010-06-18 | 2012-01-05 | Interdigital Patent Holdings, Inc. | Method and apparatus for supporting home node-b mobility |
| JP2013535456A (ja) | 2010-07-28 | 2013-09-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 呼吸器系及び炎症性疾患の治療用医薬組成物 |
| TR201009398A2 (tr) | 2010-11-11 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Fiziksel özellikleri geliştirilmiş tablet formülasyonları |
| WO2012092594A2 (en) | 2010-12-30 | 2012-07-05 | Harish Ziv M D | Preparations for topical prevention and/or treatment of oral allergic symptoms due to oral contact with fruits and/or vegetables |
| US20130030009A1 (en) | 2010-12-30 | 2013-01-31 | Ziv Harish | Method for the treatment and/or prevention of oral allergic symptions of the lips due to oral contact with a food allergen |
| KR20140020321A (ko) * | 2011-04-13 | 2014-02-18 | 레발레시오 코퍼레이션 | 염증성 신경변성 질환에 관여하는 작동자 ｔ 세포를 억제하고／하거나 조절하기 위한 조성물 및 방법 |
| EP2520292A1 (en) | 2011-05-06 | 2012-11-07 | Helmholtz-Zentrum für Infektionsforschung GmbH | Use of spirangiens for the treatment or prevention of IL-8 or IL-6 mediated disorders |
| KR20130009553A (ko) | 2011-07-15 | 2013-01-23 | 한미약품 주식회사 | 몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제 |
| CA2843022C (en) | 2011-07-26 | 2019-09-24 | Boehringer Ingelheim International Gmbh | Substituted quinolines and their use as medicaments |
| CN102895661A (zh) | 2011-07-28 | 2013-01-30 | 中国科学院上海药物研究所 | 靶向CysLT1的药物在制备用于预防或治疗自身免疫性疾病的药物中的用途 |
| SG11201406142XA (en) * | 2012-03-27 | 2014-10-30 | Univ Duke | Compositions and methods for the prevention and treatment of mast cell-induced vascular leakage |
| CN103505731A (zh) * | 2012-06-15 | 2014-01-15 | 中国药科大学 | 1型半胱氨酰白三烯受体拮抗剂在制备用于治疗阿尔茨海默病的药物中的用途 |
| WO2014090990A1 (en) | 2012-12-13 | 2014-06-19 | Ludwig Aigner | Leukotriene pathway antagonists for the treatment of dementia, cognitive deficits in parkinson's disease and/or learning and memory deficiencies in parkinson's disease |
| RU2015134423A (ru) | 2013-03-13 | 2017-04-26 | Инфламматори Респонс Ресёрч, Инк. | Применение левоцитиризина и монтелукаста при лечении аутоиммуных расстройств |
| AU2014249531B2 (en) | 2013-03-13 | 2018-11-29 | IRR, Inc. | Use of levocetirizine and montelukast in the treatment of traumatic injury |
| EP2968309A4 (en) | 2013-03-13 | 2016-08-31 | Inflammatory Response Res Inc | USE OF LEVOCETRIXIN AND MONTELUKAST IN THE TREATMENT OF VASCULARITY |
| CN105163806A (zh) | 2013-03-13 | 2015-12-16 | 炎症反应研究公司 | 左西替利嗪和孟鲁司特在治疗过敏反应中的用途 |
| US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
| WO2016044095A1 (en) * | 2014-09-15 | 2016-03-24 | Inflammatory Response Research, Inc. | Levocetirizine and montelukast in the treatment of inflammation mediated conditions |
| JP2019517581A (ja) | 2016-06-03 | 2019-06-24 | アイ・アール・アール・インコーポレイテッド | 放射線媒介性状態の処置におけるレボセチリジン及びモンテルカスト |
| WO2021236518A1 (en) | 2020-05-19 | 2021-11-25 | IRR, Inc. | Levocetirizine and montelukast in the treatment of sepsis and symptoms thereof |
-
2015
- 2015-09-11 WO PCT/US2015/049767 patent/WO2016044095A1/en not_active Ceased
- 2015-09-11 JP JP2017514446A patent/JP2017526728A/ja active Pending
- 2015-09-11 EP EP15841696.6A patent/EP3193875B1/en active Active
-
2017
- 2017-03-06 US US15/450,840 patent/US9925183B2/en active Active
-
2018
- 2018-02-13 US US15/895,918 patent/US10195193B2/en active Active
- 2018-12-18 US US16/224,573 patent/US10792281B2/en active Active
-
2020
- 2020-04-09 JP JP2020070422A patent/JP2020109128A/ja active Pending
- 2020-08-31 US US17/007,902 patent/US11590125B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX381187B (es) | Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales. | |
| DOP2022000056A (es) | Profármacos antivirales y formulaciones de los mismos | |
| BR112017005917A2 (pt) | processos e composições para indução de imunidade protetora contra infecção com o vírus da imunodeficiência humana | |
| PH12018550148A1 (en) | Hepatitis b antiviral agents | |
| WO2017044507A3 (en) | Sirna/nanoparticle formulations for treatment of middle-east respiratory syndrome coronaviral infection | |
| MY194313A (en) | Substituted chromanes and method of use | |
| NZ732391A (en) | Polycyclic-carbamoylpyridone compounds and their pharmaceutical use | |
| EA202190602A2 (ru) | 2'-замещенные-n6-замещенные пуриновые нуклеотиды для лечения вызванных рнк-вирусом заболеваний | |
| JP2015038149A5 (enExample) | ||
| JOP20210249A1 (ar) | مشتقات البيرميدون الحلقية المدمجة للاستخدام في علاج عدوىhbv أو الأمراض التي يسببها فيروس hbv | |
| PH12020551709A1 (en) | Antiviral immunotropic agent for the treatment of acute respiratory viral infections | |
| MY154683A (en) | Pharmaceutical composition for a hepatitis c viral protease inhibitor | |
| MX2019013815A (es) | Inhibidor de antigenos de superficie del virus de la hepatitis b. | |
| MY191515A (en) | Tenofovir monobenzyl ester phosphamide prodrug, preparation method and use thereof | |
| MX2017012272A (es) | Solucion para inhalacion de tiotropio para nebulizacion. | |
| DOP2017000086A (es) | Composiciones farmacéuticas de acción prolongada | |
| MY194471A (en) | Dihydropyrimidine compound and preparation method and use thereof | |
| PH12018502735A1 (en) | Liver delivery-based antiviral precursor drug nucleoside cyclophosphate compound and use thereof | |
| PH12014502551B1 (en) | Oligonucleotide chelate complex-polypeptide compositions and methods | |
| HRP20210361T1 (hr) | Upotreba pripravka koji sadrži gliceril-tribenzoat kod neurodegenerativnih poremećaja | |
| EA202092814A1 (ru) | Пиридоновое производное, его композиция и применение в качестве противовирусного лекарственного средства | |
| DOP2017000114A (es) | Composiciones farmacéuticas de acción prolongada para hepatitis c | |
| DOP2017000116A (es) | Composiciones de acción prolongada de combinación y procedimientos para hepatitis c | |
| MX2019003720A (es) | Composiciones y metodos para tratar el mal de alzheimer y la enfermedad de parkinson. | |
| JP2018536697A5 (enExample) |